NCT06568861View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 14, 2025

Primary Completion Date

July 28, 2025

Study Completion Date

July 28, 2025

Conditions
COVID-19
Interventions
DRUG

ALG-097558

Multiple doses of ALG-097558 200 mg (2 x 100 mg tablets)

Trial Locations (2)

32809

Orlando Clinical Research Center, Orlando

33136

University of Miami, Miami

Sponsors
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Aligos Therapeutics

INDUSTRY

NCT06568861 - A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function | Biotech Hunter | Biotech Hunter